- You are here: Home
- Life Science Articles
- Investigation of Simplified Physiologically-Based Pharmacokinetic Models
About Us
-
Cell Services
- Cell Line Authentication
- Cell Surface Marker Validation Service
-
Cell Line Testing and Assays
- Toxicology Assay
- Drug-Resistant Cell Models
- Cell Viability Assays
- Cell Proliferation Assays
- Cell Migration Assays
- Soft Agar Colony Formation Assay Service
- SRB Assay
- Cell Apoptosis Assays
- Cell Cycle Assays
- Cell Angiogenesis Assays
- DNA/RNA Extraction
- Custom Cell & Tissue Lysate Service
- Cellular Phosphorylation Assays
- Stability Testing
- Sterility Testing
- Endotoxin Detection and Removal
- Phagocytosis Assays
- Cell-Based Screening and Profiling Services
- 3D-Based Services
- Custom Cell Services
- Cell-based LNP Evaluation
-
Stem Cell Research
- iPSC Generation
- iPSC Characterization
-
iPSC Differentiation
- Neural Stem Cells Differentiation Service from iPSC
- Astrocyte Differentiation Service from iPSC
- Retinal Pigment Epithelium (RPE) Differentiation Service from iPSC
- Cardiomyocyte Differentiation Service from iPSC
- T Cell, NK Cell Differentiation Service from iPSC
- Hepatocyte Differentiation Service from iPSC
- Beta Cell Differentiation Service from iPSC
- Brain Organoid Differentiation Service from iPSC
- Cardiac Organoid Differentiation Service from iPSC
- Kidney Organoid Differentiation Service from iPSC
- GABAnergic Neuron Differentiation Service from iPSC
- Undifferentiated iPSC Detection
- iPSC Gene Editing
- iPSC Expanding Service
- MSC Services
- Stem Cell Assay Development and Screening
- Cell Immortalization
-
ISH/FISH Services
- In Situ Hybridization (ISH) & RNAscope Service
- Fluorescent In Situ Hybridization
- FISH Probe Design, Synthesis and Testing Service
-
FISH Applications
- Multicolor FISH (M-FISH) Analysis
- Chromosome Analysis of ES and iPS Cells
- RNA FISH in Plant Service
- Mouse Model and PDX Analysis (FISH)
- Cell Transplantation Analysis (FISH)
- In Situ Detection of CAR-T Cells & Oncolytic Viruses
- CAR-T/CAR-NK Target Assessment Service (ISH)
- ImmunoFISH Analysis (FISH+IHC)
- Splice Variant Analysis (FISH)
- Telomere Length Analysis (Q-FISH)
- Telomere Length Analysis (qPCR assay)
- FISH Analysis of Microorganisms
- Neoplasms FISH Analysis
- CARD-FISH for Environmental Microorganisms (FISH)
- FISH Quality Control Services
- QuantiGene Plex Assay
- Circulating Tumor Cell (CTC) FISH
- mtRNA Analysis (FISH)
- In Situ Detection of Chemokines/Cytokines
- In Situ Detection of Virus
- Transgene Mapping (FISH)
- Transgene Mapping (Locus Amplification & Sequencing)
- Stable Cell Line Genetic Stability Testing
- Genetic Stability Testing (Locus Amplification & Sequencing + ddPCR)
- Clonality Analysis Service (FISH)
- Karyotyping (G-banded) Service
- Animal Chromosome Analysis (G-banded) Service
- AAV Biodistribution Analysis (RNA ISH)
- Molecular Karyotyping (aCGH)
- Droplet Digital PCR (ddPCR) Service
- Digital ISH Image Quantification and Statistical Analysis
- SCE (Sister Chromatid Exchange) Analysis
- Biosample Services
- Histology Services
- Exosome Research Services
- In Vitro DMPK Services
-
In Vivo DMPK Services
- Pharmacokinetic and Toxicokinetic
- PK/PD Biomarker Analysis
- Bioavailability and Bioequivalence
- Bioanalytical Package
- Metabolite Profiling and Identification
- In Vivo Toxicity Study
- Mass Balance, Excretion and Expired Air Collection
- Administration Routes and Biofluid Sampling
- Quantitative Tissue Distribution
- Target Tissue Exposure
- In Vivo Blood-Brain-Barrier Assay
- Drug Toxicity Services
Investigation of Simplified Physiologically-Based Pharmacokinetic Models
CPT Pharmacometrics and Systems Pharmacology. 2023 Mar; 12 (3): 333-345.
Authors: Yau E, Olivares-Morales A, Ogungbenro K, Aarons L, Gertz M.
INTRODUCTION
Physiologically-based pharmacokinetic (PBPK) modeling provides a powerful tool for integrating preclinical and in vitro data in a model for human pharmacokinetic (PK) predictions. It is often necessary to inform these models with animal or clinical data, update model parameters, and make the model more predictive for future applications. This work aimed to propose new mechanistic model structures with reduced complexity allowing for parameter optimization.
METHODS
- Two distinct approaches were investigated to simplify the PBPK model structure and/or reduce the number of parameters to facilitate parameter estimation, as shown in the following figure. Kinetic lumping reduces the complexity of the model from a mathematical point of view. In contrast, steady-state commonality in drug partitioning reduces the number of unknown parameters while mostly retaining the kinetic structure of the PBPK model.
Fig. 1 Approaches investigated for simplifying a whole-PBPK model.
- Lumped body physiologically-based pharmacokinetic model with three compartments. For the three-compartment PBPK model, the lungs, venous, and arterial (serial tissues) compartments were lumped as one "central" compartment. This model specification implies a rapidly-(central), a moderately-(peripheral 1), and a slowly-(peripheral 2) equilibrating compartment. Tissues were attributed to one of the latter two compartments depending on the percentage difference and magnitude of the tissue time constants.
- Physiologically-based pharmacokinetic model with common Kpus or common scalars. Compared to the previously lumped PBPK model, the 14-compartmental PBPK model only makes the kinetic assumption that the lungs, venous, and arterial blood equilibrate quasi-instantaneously. This PBPK model is primarily based on similarity in tissue composition or steady-state drug partitioning while individual tissue blood flows and volumes are preserved compared to a full PBPK model.
- Browse our recommendations
Creative Bioarray provides professional PK testing services to help our customers choose pharmaceutical compounds and effective and safe dosing regimens. In addition, our related services include PK/PD Biomarker Analysis, Bioavailability and Bioequivalence, Bioanalytical Package, Administration Routes and Biofluid Sampling, Blood-Brain-Barrier Assay, In Vivo Toxicity Study, etc.
RESULTS
- The proposed PBPK models were further investigated for parameter estimation using diazepam data in humans and rats. Initial exploration of structural models revealed that a linear two-compartment model best described the concentration-time profiles of diazepam in humans whereas a linear three-compartment model best described the rat data.
- All PBPK models could be successfully fitted to diazepam data in humans, and all estimated a Vss value within 20%-25% of the observed value (145 L). Estimated Kpu values from the investigated models were similar.
SUMMARY
In this work, two approaches for simplifying whole-body PBPK models were investigated. For diazepam, both approaches produced models which generally showed a good ability to describe in vivo data and to estimate parameters relating to drug clearance and distribution.
RELATED PRODUCTS & SERVICES
Reference
- Yau E, et al. (2023). "Investigation of simplified physiologically-based pharmacokinetic models in rat and human." CPT Pharmacometrics Syst Pharmacol. 12 (3), 333-345.
For research use only. Not for any other purpose.